company background image
6922 logo

Cryofocus Medtech (Shanghai) SEHK:6922 Stock Report

Last Price

HK$9.51

Market Cap

HK$2.3b

7D

-2.9%

1Y

-50.0%

Updated

28 Mar, 2024

Data

Company Financials +

Cryofocus Medtech (Shanghai) Co., Ltd.

SEHK:6922 Stock Report

Market Cap: HK$2.3b

6922 Stock Overview

Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, develops, produces, and sells minimally-invasive interventional cryotherapy products in the People’s Republic of China.

6922 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cryofocus Medtech (Shanghai) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cryofocus Medtech (Shanghai)
Historical stock prices
Current Share PriceHK$9.51
52 Week HighHK$19.50
52 Week LowHK$6.00
Beta0
1 Month Change-14.32%
3 Month Change-49.47%
1 Year Change-50.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.15%

Recent News & Updates

We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Jan 10
We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Oct 03
Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Recent updates

We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Jan 10
We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Oct 03
Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth

May 30
Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth

Shareholder Returns

6922HK Medical EquipmentHK Market
7D-2.9%-4.9%-0.6%
1Y-50.0%-50.2%-14.0%

Return vs Industry: 6922 matched the Hong Kong Medical Equipment industry which returned -50.2% over the past year.

Return vs Market: 6922 underperformed the Hong Kong Market which returned -14% over the past year.

Price Volatility

Is 6922's price volatile compared to industry and market?
6922 volatility
6922 Average Weekly Movement8.0%
Medical Equipment Industry Average Movement7.8%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.6%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6922's share price has been volatile over the past 3 months.

Volatility Over Time: 6922's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013384Jun Zhuhttps://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, develops, produces, and sells minimally-invasive interventional cryotherapy products in the People’s Republic of China. The company develops products in the areas of vascular interventional therapy for the treatment of atrial fibrillation, hypertension, and other cardiovascular diseases; and natural orifice transluminal endoscopic surgery for the treatment of urinary, respiratory, and digestive diseases. Its products include Bladder Cryoablation System, a cryotherapy device for the treatment of non-muscle-invasive bladder cancer; and the Endoscopic Clip for Anastomosis, an anastomotic device for closure of soft tissue in digestive tract.

Cryofocus Medtech (Shanghai) Co., Ltd. Fundamentals Summary

How do Cryofocus Medtech (Shanghai)'s earnings and revenue compare to its market cap?
6922 fundamental statistics
Market capHK$2.27b
Earnings (TTM)-HK$105.53m
Revenue (TTM)HK$44.33m

51.3x

P/S Ratio

-21.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6922 income statement (TTM)
RevenueCN¥40.95m
Cost of RevenueCN¥9.90m
Gross ProfitCN¥31.05m
Other ExpensesCN¥128.54m
Earnings-CN¥97.49m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin75.83%
Net Profit Margin-238.06%
Debt/Equity Ratio0%

How did 6922 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.